title: RESOLUTION OF A GIANT PIGMENT EPITHELIAL DETACHMENT WITH HALF-DOSE AFLIBERCEPT.
abstract: OBJECTIVE
  To describe the use of half-dose anti-vascular endothelial growth factor therapy in a patient with giant pigment epithelial detachments.
  
  
  METHODS
  Observational case report. A 76-year-old woman with neovascular age-related macular degeneration presented with massive bilateral pigment epithelial detachments measuring over 1000 μm in height. Her right eye was treated with standard-dose aflibercept, which led to two large retinal pigment epithelium tears. Treatment of the left eye with half-dose aflibercept led to complete resolution of the detachment without tear formation.
  
  
  RESULTS
  Half-dose anti-vascular endothelial growth factor therapy resulted in resolution of a giant pigment epithelial detachment ∼1500 μm in maximal height and 10 mm in diameter.
  
  
  CONCLUSIONS
  Reduced-dose anti-vascular endothelial growth factor therapy may be considered as a treatment option for very large pigment epithelial detachments at high risk for retinal pigment epithelium tear formation.
authors.affiliation: *Division of Retinal Disorders and Ophthalmic Genetics, Stein Eye Institute, Los Angeles, California; †Doheny Eye Institute, Los Angeles, California; and ‡Division of Retina, Stein Eye Institute, University of California Los Angeles Geffen School of Medicine, Los Angeles, California.
authors.forename: Aaron
authors.initials: A
authors.lastname: Nagiel
authors.forename: Srinivas R
authors.initials: SR
authors.lastname: Sadda
authors.forename: Steven D
authors.initials: SD
authors.lastname: Schwartz
authors.forename: David
authors.initials: D
authors.lastname: Sarraf
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000150:complications; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012163:Retinal Detachment / Q000188:drug therapy*; D055213:Retinal Pigment Epithelium / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor